🇺🇸 Empagliflozin 10 MG in United States

11 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Anaphylactic Reaction — 2 reports (18.18%)
  2. Acute Respiratory Distress Syndrome — 1 report (9.09%)
  3. Acute Respiratory Failure — 1 report (9.09%)
  4. Adverse Drug Reaction — 1 report (9.09%)
  5. Anaphylactic Shock — 1 report (9.09%)
  6. Anticoagulation Drug Level — 1 report (9.09%)
  7. Blood Pressure Systolic Increased — 1 report (9.09%)
  8. Burning Sensation — 1 report (9.09%)
  9. Cardiac Arrest — 1 report (9.09%)
  10. Cerebellar Haemorrhage — 1 report (9.09%)

Source database →

Empagliflozin 10 MG in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is Empagliflozin 10 MG approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for Empagliflozin 10 MG in United States?

Tanta University is the originator. The local marketing authorisation holder may differ — check the official source linked above.